No Matches Found

Loading...
{{stock_short.stock.stock_name.value}}
{{stock_short.stock.price.value}}
{{stock_short.stock.price_difference.value}} ({{stock_short.stock.price_percentage.value}}%)
{{ra.field}}
{{ra.stock_return.chgp}}%
{{ra.sensex_return.chgp}}%
{{stock_short.result_details[0].header}}
{{stock_short.result_details[0].latest.to_period}}
{{stock_short.result_details[0].latest.from_period}}
Change%
{{latest.field}}
{{latest.to}}{{latest.value_suffix}}
{{latest.from}}{{latest.value_suffix}}
{{latest.per}}
Figures in Rs cr

What does Revance Therapeutics, Inc. do?

Revance Therapeutics, Inc. is a biotechnology company specializing in aesthetic and therapeutic pharmaceuticals, with a market cap of $381.02 million and quarterly net sales of $60 million but a net loss of $38 million as of September 2024.

Jun 22 2025 06:29 PM IST
share
Share Via

How big is Revance Therapeutics, Inc.?

As of Feb 07, Revance Therapeutics, Inc. has a market capitalization of 381.02 million and reported net sales of 247.01 million with a net profit of -180.81 million over the latest four quarters. Shareholder's funds are at -151.60 million, and total assets amount to 478.45 million.

Jun 22 2025 05:52 PM IST
share
Share Via

{{list.post_title}}

{{list.post_excerpt}}

{{list.post_date_sep}}
share
Share Via
{{list.post_title_sep}}

{{list.post_title}}

{{list.post_excerpt}}

{{list.post_date_sep}}
share
Share Via

Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Most Read